Combined approach for embolization of otherwise unmanageable gastric varices.
Gastrointestinal hemorrhage
balloon-occluded retrograde transvenous obliteration
gastric varices
percutaneous transhepatic obliteration
portal hypertension
Journal
Annals of gastroenterology
ISSN: 1108-7471
Titre abrégé: Ann Gastroenterol
Pays: Greece
ID NLM: 101121847
Informations de publication
Date de publication:
Historique:
received:
26
11
2020
accepted:
28
01
2021
entrez:
19
7
2021
pubmed:
20
7
2021
medline:
20
7
2021
Statut:
ppublish
Résumé
This study aimed to determine the feasibility, safety and effectiveness of combined percutaneous transhepatic obliteration (PTO) and balloon-occluded retrograde transvenous obliteration (BRTO) therapy for the treatment of patients with high-risk bleeding gastric varices. Ten patients were retrospectively reviewed. All the patients presented gastric varices, according to the Sarin classification, at high risk of bleeding, and not otherwise manageable. Patients with portal vein thrombosis were excluded. All patients were treated with a combination of PTO and BRTO. In all cases the gastric varices were embolized with glue, combined with coils or not, with an occlusion balloon inflated into the shunt. In 7 cases, embolization was immediate; in the remaining 3 the balloon remained inflated for 4 h and in 2 of them embolization of the shunt was required. Technical success was defined as complete obliteration of the gastric varices observed during a contrast-enhanced computed tomography study and endoscopy within 1 month following treatment. Clinical success was defined as absence of bleeding of gastric varices during the follow-up period. Major and minor complications during the follow up were recorded. Twelve sessions of combined PTO and BRTO procedures were performed in 10 patients; in 2 patients a new combined treatment was required during the follow up. Technical and clinical success was 100%. Neither major nor minor procedure-related complications were observed. Combined PTO and BRTO therapy is safe and effective for the treatment of gastric varices that cannot be managed otherwise.
Sections du résumé
BACKGROUND
BACKGROUND
This study aimed to determine the feasibility, safety and effectiveness of combined percutaneous transhepatic obliteration (PTO) and balloon-occluded retrograde transvenous obliteration (BRTO) therapy for the treatment of patients with high-risk bleeding gastric varices.
METHODS
METHODS
Ten patients were retrospectively reviewed. All the patients presented gastric varices, according to the Sarin classification, at high risk of bleeding, and not otherwise manageable. Patients with portal vein thrombosis were excluded. All patients were treated with a combination of PTO and BRTO. In all cases the gastric varices were embolized with glue, combined with coils or not, with an occlusion balloon inflated into the shunt. In 7 cases, embolization was immediate; in the remaining 3 the balloon remained inflated for 4 h and in 2 of them embolization of the shunt was required. Technical success was defined as complete obliteration of the gastric varices observed during a contrast-enhanced computed tomography study and endoscopy within 1 month following treatment. Clinical success was defined as absence of bleeding of gastric varices during the follow-up period. Major and minor complications during the follow up were recorded.
RESULTS
RESULTS
Twelve sessions of combined PTO and BRTO procedures were performed in 10 patients; in 2 patients a new combined treatment was required during the follow up. Technical and clinical success was 100%. Neither major nor minor procedure-related complications were observed.
CONCLUSION
CONCLUSIONS
Combined PTO and BRTO therapy is safe and effective for the treatment of gastric varices that cannot be managed otherwise.
Identifiants
pubmed: 34276189
doi: 10.20524/aog.2021.0616
pii: AnnGastroenterol-34-510
pmc: PMC8276367
doi:
Types de publication
Journal Article
Langues
eng
Pagination
510-515Informations de copyright
Copyright: © Hellenic Society of Gastroenterology.
Déclaration de conflit d'intérêts
Conflict of Interest: None
Références
Dig Dis Sci. 2015 Jun;60(6):1543-53
pubmed: 25519690
Tech Vasc Interv Radiol. 2013 Jun;16(2):101-51
pubmed: 23830671
Hepatology. 2017 Jan;65(1):310-335
pubmed: 27786365
J Hepatol. 2015 Sep;63(3):543-5
pubmed: 26150255
Biomed Rep. 2017 Jan;6(1):99-102
pubmed: 28123716
Hepatology. 2019 Jan;69(1):282-293
pubmed: 30014519
Am J Gastroenterol. 2021 Apr;116(4):838-840
pubmed: 33982964
Korean J Radiol. 2018 Mar-Apr;19(2):223-229
pubmed: 29520179
Gut. 2015 Nov;64(11):1680-704
pubmed: 25887380
Semin Intervent Radiol. 2018 Aug;35(3):169-184
pubmed: 30087520
Acta Biomed. 2020 Jul 13;91(8-S):71-80
pubmed: 32945281
World J Hepatol. 2019 Mar 27;11(3):250-260
pubmed: 30967903
ScientificWorldJournal. 2013 Dec 21;2013:498535
pubmed: 24453866
Hepatology. 1992 Dec;16(6):1343-9
pubmed: 1446890
World J Radiol. 2012 Mar 28;4(3):121-5
pubmed: 22468194
Korean J Radiol. 2016 Mar-Apr;17(2):230-8
pubmed: 26957908
Tech Vasc Interv Radiol. 2012 Sep;15(3):203-25
pubmed: 23021832
Tech Vasc Interv Radiol. 2013 Jun;16(2):59
pubmed: 23830669
Semin Intervent Radiol. 2011 Sep;28(3):314-24
pubmed: 22942549
World J Gastroenterol. 2006 Jun 28;12(24):3866-73
pubmed: 16804972
Tech Vasc Interv Radiol. 2013 Jun;16(2):60-100
pubmed: 23830670
Semin Intervent Radiol. 2018 Aug;35(3):185-193
pubmed: 30087521
Gastroenterology. 2021 Jan;160(1):193-205.e10
pubmed: 32980344
J Vasc Interv Radiol. 2003 Sep;14(9 Pt 2):S199-202
pubmed: 14514818
World J Gastrointest Pharmacol Ther. 2019 Jan 21;10(1):1-21
pubmed: 30697445
J Gastroenterol Hepatol. 1996 Jan;11(1):51-8
pubmed: 8672742
Yonsei Med J. 2016 Jul;57(4):973-9
pubmed: 27189294